Thalia Therapeutics - New article: RNA medicine enters its second act
Summary
The RNA therapeutics market continues to gather momentum, presenting significant opportunities for innovation and value creation.
In the latest European Biotechnology Magazine RNA Technologies Special, Thalia Therapeutics CEO Dr David Solomon discusses the company's strategic focus on RNA therapeutics, the potential for new RNA modalities including microRNAs and the opportunity to address new therapeutic areas such as cardiovascular disease and oncology.
Read the full article here: https://issuu.com/biocom/docs/ebm_2026_rna_special?fr=sMjMyYTgzNTg2MzQ
Your question will be sent privately to Thalia Therapeutics. The company may choose to make this question public.
Start the conversation
Ask Thalia Therapeutics a question about this announcement.
Share your feedback
Discover